aTyr Pharma Q1 2022 cash $98.7M; on track for registrational study in pulmonary sarcoidosis

aTYR PHARMA INC

2023-Q1 EPS reported -$0.44

Cash and investments $98.7M at March 31, 2022; R&D expenses $8.9M, G&A $3.5M.
Phase 1b/2a efzofitimod data to be presented at ATS 2022; registrational study planned for Q3 2022.
FDA orphan drug designation for efzofitimod in systemic sclerosis; exploring expansion into other ILDs.
ATYR2810 IND candidate; Phase 1 study in cancer expected in H2 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.